<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>matt-kaeberlein on AndArds</title>
    <link>https://andards.com/tags/matt-kaeberlein/</link>
    <description>Recent content in matt-kaeberlein on AndArds</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 05 Mar 2026 22:40:00 +0000</lastBuildDate><atom:link href="https://andards.com/tags/matt-kaeberlein/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Rapamycin for Longevity: The Current Human Trials and What We Know</title>
      <link>https://andards.com/posts/rapamycin-for-longevity-the-current-human-trials-and-what-we-know/</link>
      <pubDate>Thu, 05 Mar 2026 22:40:00 +0000</pubDate>
      
      <guid>https://andards.com/posts/rapamycin-for-longevity-the-current-human-trials-and-what-we-know/</guid>
      <description>Rapamycin, an immunosuppressant drug, has garnered significant attention in the longevity research community due to its documented ability to extend lifespan in various organisms. This article explores the current landscape of human trials investigating rapamycin for longevity, examining the scientific basis, ongoing studies, and the cautious optimism surrounding its potential as an anti-aging drug.</description>
    </item>
    
    <item>
      <title>The Dog Aging Project: What Matt Kaeberlein is Learning from Our Pets</title>
      <link>https://andards.com/posts/the-dog-aging-project-what-matt-kaeberlein-is-learning-from-our-pets/</link>
      <pubDate>Sun, 01 Mar 2026 20:58:00 +0000</pubDate>
      
      <guid>https://andards.com/posts/the-dog-aging-project-what-matt-kaeberlein-is-learning-from-our-pets/</guid>
      <description>The Dog Aging Project is a large-scale, longitudinal study investigating how genetics, lifestyle, and environment influence the health and longevity of companion dogs. Led by Dr. Matt Kaeberlein, a prominent researcher in the biology of aging, the project aims to gather extensive data from tens of thousands of dogs across the United States.</description>
    </item>
    
    <item>
      <title>Matt Kaeberlein&#39;s Rapamycin Research: The Most Promising Longevity Drug?</title>
      <link>https://andards.com/posts/matt-kaeberleins-rapamycin-research-the-most-promising-longevity-drug/</link>
      <pubDate>Tue, 24 Feb 2026 19:47:00 +0000</pubDate>
      
      <guid>https://andards.com/posts/matt-kaeberleins-rapamycin-research-the-most-promising-longevity-drug/</guid>
      <description>Rapamycin, an immunosuppressant drug discovered in the 1970s, has garnered significant attention in the longevity research community. Among the key figures exploring its potential to extend healthy lifespan is Dr. Matt Kaeberlein, a professor of laboratory medicine and pathology at the University of Washington.</description>
    </item>
    
    <item>
      <title>Matt Kaeberlein and the Dog Aging Project: What Rapamycin Does for Pets</title>
      <link>https://andards.com/posts/matt-kaeberlein-and-the-dog-aging-project-what-rapamycin-does-for-pets/</link>
      <pubDate>Sun, 04 Jan 2026 21:18:00 +0000</pubDate>
      
      <guid>https://andards.com/posts/matt-kaeberlein-and-the-dog-aging-project-what-rapamycin-does-for-pets/</guid>
      <description>The prospect of extending healthy lifespan, for humans and their animal companions, drives much research in geroscience. At the forefront of this effort is Dr. Matt Kaeberlein, a recognized figure in aging research, and his involvement with the Dog Aging Project.</description>
    </item>
    
  </channel>
</rss>
